Prescient Therapeutics (ASX:PTX) to begin three next-gen CAR T programs
Prescient Therapeutics (PTX) has announced three internal development programs for its immune receptor technology platform,...
Prescient Therapeutics (PTX) has announced three internal development programs for its immune receptor technology platform,...
Following more than a decade of treatments, cancer survivor Laurie Adami now plans to tackle...
An American woman who owes her life to a bespoke cancer treatment is speaking out...
Laurie Adami has had a long and intricate journey with blood cancer, after being diagnosed...
When local synthetic antibiotics developer Recce Pharmaceuticals announced they had entered into an antiviral Sars-CoV-2...
Prescient Therapeutics (ASX: PTX) Chief Executive Officer Steven Yatomi-Clarke joins Small Caps to discuss the...
PTX has acquired the exclusive global licence to a universal immune receptor (UIR) platform from...
We maintain our Buy rating and are increasing our price target to A$0.20 from A$0.16...
We maintain our Buy rating and are increasing our price target to A$0.16from A$0.09. The...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.